SRRK — Scholar Rock Holding Corporatio

Is SRRK overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Scholar Rock Holding Corporatio (SRRK) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $44.54. The rating moved from Oversold to Strong Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Scholar Rock Holding Corporatio (SRRK) is a development‑stage biotech with upside tied to clinical and partnership outcomes but limited near‑term visibility on financial health in the provided data. Market conditions in the last several hours show risk‑off positioning and rotation toward defensive large‑cap pharma and utilities, which reduces appetite for speculative names. Potential catalysts include positive clinical readouts or strategic partnerships, while primary challenges are cash runway, dilutive financing risk, competitive pressure from larger pharma, and evolving reimbursement/regulatory dynamics. Given current information gaps, the near‑term outlook is cautious with outcomes highly binary depending on clinical and financing developments.

Key factors

  • Pipeline focus on novel biologics with potential high upside if clinical readouts are positive
  • Limited publicly available recent financial filings in the provided dataset, increasing uncertainty about cash runway and near‑term financing needs
  • Sector tailwinds toward large‑cap pharma and specialty franchises could provide M&A or partnership interest for attractive biotech assets
  • Defensive market tone and rotation into staples/utilities suggest limited near‑term appetite for speculative biotech upside
  • Regulatory environment (Medicare/Medicaid/CHIP program integrity) could indirectly pressure commercialization economics for therapeutics tied to reimbursement-sensitive markets
  • Lack of social sentiment and EDGAR analysis in the provided inputs reduces visibility into market perception and insider/insitutional positioning

Risks

  • Clinical trial failures or negative readouts that materially reduce valuation
  • High cash burn and the need for dilutive financing before achieving meaningful revenue
  • Competition and consolidation from large‑cap pharma with deeper commercial and regulatory resources
  • Regulatory and reimbursement pressures (e.g., Medicare program integrity initiatives) that could constrain pricing or uptake
  • Limited near‑term liquidity and trading volatility given small‑cap biotech characteristics
  • Absence of recent, detailed filings or social/research signals in the provided data set, increasing information risk

See today's live rating, score and targets

Members see the live hourly rating for SRRK — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.